Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Biliary Tract Diseases

  Free Subscription

Articles published in J Hepatol

Retrieve available abstracts of 177 articles:
HTML format

Single Articles

    July 2021
  1. LODATO F, Larocca A, D'Errico A, Cennamo V, et al
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01904.

  2. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.

    June 2021
  3. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    PubMed     Abstract available

  4. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.

  5. ZHANG Y, Zuo C, Liu L, Hu Y, et al
    Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00442.
    PubMed     Abstract available

    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.

    May 2021
  7. SONG X, Xu H, Wang P, Wang J, et al
    Focal Adhesion Kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00353.
    PubMed     Abstract available

  8. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
    J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
    PubMed     Abstract available

  9. BOULTER L, Ebrahimkhani MR
    Build to understand biliary oncogenesis via organoids and FGFR2 fusion proteins.
    J Hepatol. 2021 May 21. pii: S0168-8278(21)00341.

  10. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.

  11. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    PubMed     Abstract available

    April 2021
  12. TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
    Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
    PubMed     Abstract available

  13. REICH M, Spomer L, Klindt C, Fuchs K, et al
    Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
    J Hepatol. 2021 Apr 16. pii: S0168-8278(21)00244.
    PubMed     Abstract available

  14. VALLEJO A, Erice O, Entrialgo-Cadierno R, Feliu I, et al
    FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.
    J Hepatol. 2021 Apr 14. pii: S0168-8278(21)00235.
    PubMed     Abstract available

    March 2021
  15. POCH T, Krause J, Casar C, Liwinski T, et al
    Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00219.
    PubMed     Abstract available

  16. DELTENRE P, Moreno C, Trepo E
    Progressive cholangiopathy in Covid-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.
    J Hepatol. 2021 Mar 19. pii: S0168-8278(21)00179.

  17. LI J, Zhu X, Zhang M, Zhang Y, et al
    Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
    PubMed     Abstract available

  18. CRISTINZIANO G, Porru M, Lamberti D, Buglioni S, et al
    FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    J Hepatol. 2021 Mar 16. pii: S0168-8278(21)00172.
    PubMed     Abstract available

    February 2021
  19. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.

  20. KEIDING S, Frisch K, Hofmann AF
    Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
    J Hepatol. 2021 Feb 20. pii: S0168-8278(21)00114.

  21. BOYER JL, Soroka CJ
    Bile formation and Secretion: An update.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00111.
    PubMed     Abstract available

  22. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.

  23. CASOLINO R, Braconi C
    CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00045.

  24. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.

  25. ROESSLER S, Edeline J, Schirmacher P, Coulouarn C, et al
    Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer.
    J Hepatol. 2021 Feb 16. pii: S0168-8278(21)00007.

  26. FABRIS L, Cadamuro M, Fouassier L
    Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche.
    J Hepatol. 2021 Feb 11. pii: S0168-8278(20)33892.

  27. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
    EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
    J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
    PubMed     Abstract available

  28. BEAUFRERE A, Calderaro J, Paradis V
    Combined hepatocellular-cholangiocarcinoma: An update.
    J Hepatol. 2021 Feb 2. pii: S0168-8278(21)00084.
    PubMed     Abstract available

    January 2021
  29. CONDE DE LA ROSA L, Garcia-Ruiz C, Vallejo C, Baulies A, et al
    STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    J Hepatol. 2021 Jan 27. pii: S0168-8278(21)00040.
    PubMed     Abstract available

    Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
    J Hepatol. 2021 Jan 25. pii: S0168-8278(21)00044.

  31. SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
    A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
    PubMed     Abstract available

  32. RAGGI C, Taddei ML, Sacco E, Navari N, et al
    Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00024.
    PubMed     Abstract available

    December 2020
  33. SARKAR M, Grab J, Irani RA
    Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?"
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33806.

  34. PHILLIPS J, Senaratne S
    Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33694.

  35. VASAVAN T, Deepak S, Jayawardane IA, Lucchini M, et al
    Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33825.
    PubMed     Abstract available

  36. DIGGS LP, Ruf B, Ma C, Heinrich B, et al
    CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33824.
    PubMed     Abstract available

  37. NEPAL C, Zhu B, O'Rourke CJ, Bhatt DK, et al
    Integrative molecular characterization of gallbladder cancer reveals microenvironment-associated subtypes.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33820.
    PubMed     Abstract available

    November 2020
  38. DWYER BJ, Jarman EJ, Gogoi-Tiwari J, Ferreira-Gonzalez S, et al
    TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.
    J Hepatol. 2020 Nov 19. pii: S0168-8278(20)33771.
    PubMed     Abstract available

  39. HUANG YH, Zhang CZ, Huang QS, Yeong J, et al
    Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33763.
    PubMed     Abstract available

  40. STEIN S, Henze L, Poch T, Carambia A, et al
    IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.
    J Hepatol. 2020 Nov 13. pii: S0168-8278(20)33759.
    PubMed     Abstract available

    October 2020
  41. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33690.
    PubMed     Abstract available

  42. CARBONE M, Ronca V, Invernizzi P
    Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.

  43. HYDES T, Khakoo SI
    A spotlight on natural killer cells in primary biliary cholangitis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.

  44. CAI SY, Yu D, Soroka CJ, Wang J, et al
    Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
    PubMed     Abstract available

    September 2020
  45. HIRSCHFIELD GM, Beuers U, Kupcinskas L, Ott P, et al
    A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33623.
    PubMed     Abstract available

  46. LEE-LAW PY, Olaizola P, Caballero-Camino FJ, Izquierdo-Sanchez L, et al
    Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33622.
    PubMed     Abstract available

  47. FABRIS L, Andersen JB, Fouassier L
    Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment.
    J Hepatol. 2020 Sep 5. pii: S0168-8278(20)30471.

  48. BALAPHAS A, Gkoufa K, Meyer J, Peloso A, et al
    Covid-19 can mimic acute cholecystitis and is associated with the presence of viral RNA in the gallbladder wall.
    J Hepatol. 2020 Sep 2. pii: S0168-8278(20)30550.

  49. DYSON JK, Jones DEJ
    UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
    J Hepatol. 2020;73:499-501.

    August 2020
  50. IZURIETA PACHECO AC, Monfort Carretero L, Prat Torres C, Garcia-Alix Perez A, et al
    NISCH syndrome: An extremely rare cause of neonatal cholestasis.
    J Hepatol. 2020 Aug 27. pii: S0168-8278(20)30459.

    July 2020
  51. KJAERGAARD K, Frisch K, Sorensen M, Munk OL, et al
    Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30481.
    PubMed     Abstract available

  52. CARBONE M, Milani C, Gerussi A, Ronca V, et al
    Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30362.

  53. DEEB M, Karlsen TH, Hirschfield GM
    The 6 C's of Primary Sclerosing Cholangitis.
    J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30436.

    Effective medical treatments for PSC needed ASAP - is AESOP the answer?
    J Hepatol. 2020;73:12-14.

    June 2020
  55. BABU RO, Hang Lui VC, Chen Y, Wan Yiu RS, et al
    Beta-amyloid deposition around hepatic bile ducts is a novel pathobiological and diagnostic feature of biliary atresia.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30383.
    PubMed     Abstract available

  56. BREVINI T, Tysoe OC, Sampaziotis F
    Tissue engineering of the biliary tract and modelling of cholestatic disorders.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30367.
    PubMed     Abstract available

  57. ZHANG M, Yang H, Wan L, Wang Z, et al
    Single cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Jun 4. pii: S0168-8278(20)30360.
    PubMed     Abstract available

  58. HARMS MH, van Buuren HR, van der Meer AJ
    Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
    J Hepatol. 2020;72:1211-1212.

  59. CORPECHOT C, Rousseau A, Chazouilleres O
    Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
    J Hepatol. 2020;72:1210-1211.

    May 2020
  60. MCNAMARA MG, Lopes A, Wasan H, Malka D, et al
    Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer.
    J Hepatol. 2020 May 21. pii: S0168-8278(20)30306.
    PubMed     Abstract available

  61. JACKSON SS, Adami HO, Andreotti G, Beane-Freeman LE, et al
    Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project.
    J Hepatol. 2020 May 10. pii: S0168-8278(20)30292.
    PubMed     Abstract available

  62. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    PubMed     Abstract available

    April 2020
  63. CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
    Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
    PubMed     Abstract available

    March 2020
  64. KHAN SA, Clements O, Kim JU, Eliahoo J, et al
    Reply to: 'Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]'.
    J Hepatol. 2020 Mar 23. pii: S0168-8278(20)30128.

  65. JIANG M, Deng H, Liu S, Su S, et al
    Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis].
    J Hepatol. 2020 Mar 17. pii: S0168-8278(20)30067.

  66. MONTAL R, Sia D, Montironi C, Leow WQ, et al
    Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Mar 12. pii: S0168-8278(20)30166.
    PubMed     Abstract available

  67. LAMARCA A, Barriuso J, McNamara MG, Valle JW, et al
    Molecular targeted therapies: ready for "prime time" in biliary tract cancer.
    J Hepatol. 2020 Mar 11. pii: S0168-8278(20)30165.
    PubMed     Abstract available

  68. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    PubMed     Abstract available

    February 2020
  69. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Genotype correlates with the natural history of severe bile salt export pump deficiency.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105.
    PubMed     Abstract available

  70. MAZZAFERRO V, Gorgen A, Roayaie S, Droz Dit Busset M, et al
    Liver resection and transplantation for intrahepatic cholangiocarcinoma.
    J Hepatol. 2020;72:364-377.
    PubMed     Abstract available

  71. KELLEY RK, Bridgewater J, Gores GJ, Zhu AX, et al
    Systemic therapies for intrahepatic cholangiocarcinoma.
    J Hepatol. 2020;72:353-363.
    PubMed     Abstract available

    January 2020
  72. PANZITT K, Jungwirth E, Krones E, Lee JM, et al
    FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
    J Hepatol. 2020 Jan 27. pii: S0168-8278(20)30031.
    PubMed     Abstract available

    December 2019
  73. DE VRIES E, Beuers U
    Reply to: "UDCA therapy in intrahepatic cholestasis of pregnancy?"
    J Hepatol. 2019 Dec 28. pii: S0168-8278(19)30705.

  74. PAISANT A, Vilgrain V, Riou J, Oberti F, et al
    Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
    PubMed     Abstract available

  75. KUMAR P, Kulkarni A
    UDCA therapy in intrahepatic cholestasis of pregnancy?
    J Hepatol. 2019 Dec 18. pii: S0168-8278(19)30653.

  76. PEI T, Meng F, Xiao P, Han J, et al
    MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    J Hepatol. 2019 Dec 11. pii: S0168-8278(19)30713.
    PubMed     Abstract available

    October 2019
  77. MEUNIER L, Meszaros M, Pageaux GP, Larrey D, et al
    Potential role of ketamine in burn-associated cholestasis.
    J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30475.

    September 2019
  78. LEGRAND M, de Tymowski C, Hodjat K, Mallet V, et al
    Reply to: "Potential role of ketamine in burn-associated cholestasis".
    J Hepatol. 2019 Sep 30. pii: S0168-8278(19)30542.

  79. BERTUCCIO P, Malvezzi M, Carioli G, Hashim D, et al
    Reply to: "Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma".
    J Hepatol. 2019 Sep 26. pii: S0168-8278(19)30527.

  80. KHANDEKAR G, Llewellyn J, Kriegermeier A, Waisbourd-Zinman O, et al
    Coordinated development of the mouse extrahepatic bile duct: implications for neonatal susceptibility to biliary injury.
    J Hepatol. 2019 Sep 25. pii: S0168-8278(19)30550.
    PubMed     Abstract available

  81. KHAN SA, Genus T, Morement H, Murphy A, et al
    Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
    J Hepatol. 2019 Sep 23. pii: S0168-8278(19)30466.

  82. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    PubMed     Abstract available

    Risk stratification in primary sclerosing cholangitis: It's time to move on from replicating imperfection and break the glass ceiling.
    J Hepatol. 2019 Sep 9. pii: S0168-8278(19)30480.

    August 2019
  84. SHETTY S, Boyer JL
    Bile acid metabolism and T cell responses in cholangiopathy: Not one-way traffic.
    J Hepatol. 2019 Aug 22. pii: S0168-8278(19)30420.

    July 2019
  85. GOET JC, Floreani A, Verhelst X, Cazzagon N, et al
    Validation, Clinical Utility and Limitations of the Amsterdam-Oxford Model for Primary Sclerosing Cholangitis.
    J Hepatol. 2019 Jul 3. pii: S0168-8278(19)30384.
    PubMed     Abstract available

    June 2019
  86. AL-DURY S, Wahlstrom A, Panzitt K, Thorell A, et al
    Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    J Hepatol. 2019 Jun 26. pii: S0168-8278(19)30383.
    PubMed     Abstract available

  87. GLASER F, John C, Engel B, Hoh B, et al
    Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis.
    J Hepatol. 2019 Jun 14. pii: S0168-8278(19)30347.
    PubMed     Abstract available

  88. WANG J, Wang H, Peters M, Ding N, et al
    Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30342.
    PubMed     Abstract available

  89. ZHOU G, Sprengers D, Mancham S, Erkens R, et al
    Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex-vivo targeting immune checkpoint molecules.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30340.
    PubMed     Abstract available

  90. RAVICHANDRAN G, Neumann K, Berkhout LK, Weidemann S, et al
    Interferon-gamma-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30309.
    PubMed     Abstract available

    May 2019
  91. DE TYMOWSKI C, Depret F, Soussi S, Nabila M, et al
    Contributing factors and outcomes of burn-associated cholestasis.
    J Hepatol. 2019 May 29. pii: S0168-8278(19)30292.
    PubMed     Abstract available

  92. DE KRIJGER M, Wildenberg ME, de Jonge WJ, Ponsioen CY, et al
    Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis.
    J Hepatol. 2019 May 17. pii: S0168-8278(19)30287.
    PubMed     Abstract available

  93. NISHIO T, Hu R, Koyama Y, Liang S, et al
    Activated Hepatic Stellate Cells and Portal Fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice.
    J Hepatol. 2019 May 6. pii: S0168-8278(19)30273.
    PubMed     Abstract available

    April 2019
  94. HARMS MH, van Buuren HR, Corpechot C, Thorburn D, et al
    Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary Biliary Cholangitis.
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30228.
    PubMed     Abstract available

  95. ALEKSIEVA N, Forbes SJ
    Biliary-derived hepatocytes in chronic liver injury: Bringing new troops to the battlefield?
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30185.

  96. OVEREEM AW, Klappe K, Parisi S, Kloters-Planchy P, et al
    Pluripotent stem cell-derived bile canaliculi-forming hepatocytes to study genetic liver diseases involving hepatocyte polarity.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30225.
    PubMed     Abstract available

    March 2019
  97. ARONSON SJ, Bakker RS, Shi X, Duijst S, et al
    Liver-directed gene therapy results in long term correction of progressive familial intrahepatic cholestasis type 3 in mice.
    J Hepatol. 2019 Mar 29. pii: S0168-8278(19)30192.
    PubMed     Abstract available

  98. BERTUCCIO P, Malvezzi M, Carioli G, Hashim D, et al
    Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
    J Hepatol. 2019 Mar 22. pii: S0168-8278(19)30183.
    PubMed     Abstract available

  99. TSUNODA T, Kakinuma S, Miyoshi M, Kamiya A, et al
    Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium.
    J Hepatol. 2019 Mar 15. pii: S0168-8278(19)30146.
    PubMed     Abstract available

  100. JAIN V, Burford C, Alexander EC, Sutton H, et al
    Prognostic markers at adolescence in patients Biliary Atresia for liver transplantation in adulthood.
    J Hepatol. 2019 Mar 12. pii: S0168-8278(19)30143.
    PubMed     Abstract available

    February 2019
  101. LAMARCA A, Barriuso J, Chander A, McNamara MG, et al
    18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30126.
    PubMed     Abstract available

  102. MANCO R, Clerbaux LA, Verhulst S, Nader MB, et al
    Reactive cholangiocytes differentiate into proliferative hepatocytes with efficient DNA repair in mice with chronic liver injury.
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30117.
    PubMed     Abstract available

  103. VERGIS N, Atkinson SR, Thursz MR
    The future of therapy for alcoholic hepatitis - Beyond corticosteroids.
    J Hepatol. 2019 Feb 18. pii: S0168-8278(19)30030.

    January 2019
  104. SCHMIDT T, Schwinge D, Rolvien T, Jeschke A, et al
    Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis.
    J Hepatol. 2019 Jan 11. pii: S0168-8278(19)30016.
    PubMed     Abstract available

  105. WU F, Wu D, Ren Y, Huang Y, et al
    Generation of hepato-biliary organoids from human induced pluripotent stem cells.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30002.
    PubMed     Abstract available

  106. TABIBIAN JH, Lindor KD
    NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter.
    J Hepatol. 2019 Jan 6. pii: S0168-8278(18)32623.

    December 2018
  107. BAUMEISTER SE, Schlesinger S, Aleksandrova K, Jochem C, et al
    Association of Physical Activity and Risk of Hepatobiliary Cancers: A Multinational Cohort Study.
    J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32633.
    PubMed     Abstract available

  108. CADAMURO M, Brivio S, Mertens J, Vismara M, et al
    Platelet-Derived Growth Factor-D Enables Liver Myofibroblasts to Promote Tumor Lymphangiogenesis in Cholangiocarcinoma.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32620.
    PubMed     Abstract available

  109. LEE S, Kim MJ, Kim S, Choi D, et al
    Intraductal Papillary Neoplasm of the Bile Duct: Assessment of Invasive Carcinoma and Long-Term Outcomes using MRI.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32621.
    PubMed     Abstract available

    November 2018
  110. HIRSCHFIELD GM, Chazouilleres O, Drenth JP, Thorburn D, et al
    Effect of NGM282, a FGF19 analogue, in Primary Sclerosing Cholangitis: a Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32519.
    PubMed     Abstract available

    October 2018
  111. DE HAAN LR, van Golen RF
    Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?
    J Hepatol. 2018 Oct 4. pii: S0168-8278(18)32382.

    September 2018
  112. TANAKA H, Imasato M, Yamazaki Y, Matsumoto K, et al
    Claudin-3 regulates bile canalicular paracellular barrier and cholesterol gallstone cores formation in mice.
    J Hepatol. 2018 Sep 10. pii: S0168-8278(18)32374.
    PubMed     Abstract available

  113. RODRIGUES PM, Perugorria MJ, Santos-Laso A, Bujanda L, et al
    Primary biliary cholangitis: a tale of epigenetically-induced secretory failure?
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32362.
    PubMed     Abstract available

    August 2018
  114. CUBERO FJ, Peng J, Liao L, Su H, et al
    Inactivation of Caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.
    J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32297.
    PubMed     Abstract available

  115. FONTANA RJ, Cirulli ET, Gu J, Kleiner D, et al
    The role of HLA-A *33:01 in Patients with Cholestatic Hepatitis attributed to Terbinafine.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32283.
    PubMed     Abstract available

    July 2018
  116. PROBERT PM, Leitch AC, Dunn MP, Meyer SK, et al
    Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis.
    J Hepatol. 2018 Jul 10. pii: S0168-8278(18)32182.
    PubMed     Abstract available

  117. PLOTON M, Mazuy C, Gheeraert C, Dubois V, et al
    The Nuclear Bile Acid Receptor FXR is a PKA- and FOXA2-Sensitive Activator of Fasting Hepatic Gluconeogenesis.
    J Hepatol. 2018 Jul 4. pii: S0168-8278(18)32175.
    PubMed     Abstract available

    June 2018
  118. BRINKERT F, Pukite I, Krebs-Schmitt D, Briem-Richter A, et al
    Allogeneic hematopoietic stem cell transplantation eliminates alloreactive inhibitory antibodies after liver transplantation for bile salt export pump deficiency.
    J Hepatol. 2018 Jun 20. pii: S0168-8278(18)32156.
    PubMed     Abstract available

  119. YANG L, Mizuochi T, Shivakumar P, Mourya R, et al
    Regulation of Epithelial Injury and Bile Duct Obstruction by NLRP3 and IL-1R1 in Experimental Biliary Atresia.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32123.
    PubMed     Abstract available

    May 2018
  120. GUICCIARDI ME, Trussoni CE, Krishnan A, Bronk SF, et al
    Macrophages Contribute to the Pathogenesis of Sclerosing Cholangitis in Mice.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32064.
    PubMed     Abstract available

  121. PEERAPHATDIT TB, Simonetto DA, Shah VH
    Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis.
    J Hepatol. 2018 May 21. pii: S0168-8278(18)32058.

  122. LIU HC, Hu XS, Pang Q, Jin H, et al
    Potential limitations of irradiation stent implantation in unresectable malignant biliary obstruction.
    J Hepatol. 2018 May 15. pii: S0168-8278(18)32021.

  123. ZHU HD, Lu J, Teng GJ
    Response to Letter to the Editor on "Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: a multicentre trial".
    J Hepatol. 2018 May 8. pii: S0168-8278(18)32049.

    April 2018
  124. POLLHEIMER MJ, Racedo S, Mikels-Vigdal A, Marshall D, et al
    Lysyl oxidase-like protein 2 (LOXL2) Modules Barrier Function in Cholangiocytes In Cholestasis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32017.
    PubMed     Abstract available

  125. BRANDL K, Hartmann P, Jih LJ, Pizzo DP, et al
    Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)31973.
    PubMed     Abstract available

    March 2018
  126. SETO WK, Mak SK, Chiu K, Vardhanabhuti V, et al
    Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30164.
    PubMed     Abstract available

  127. DONG LQ, Shi Y, Ma LJ, Yang LX, et al
    Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30167.
    PubMed     Abstract available

  128. SCHNEIDER KM, Albers S, Trautwein C
    Role of bile acids in the gut-liver axis.
    J Hepatol. 2018 Mar 5. pii: S0168-8278(17)32450.

    February 2018
  129. SHA M, Jeong S, Xia Q
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection: Novel Concerns.
    J Hepatol. 2018 Feb 20. pii: S0168-8278(18)30122.

  130. LI J, Lei Z, Wang K, Shen F, et al
    Reply to "Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: novel concerns".
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30127.

  131. KIM AY, Sinn DH, Jeong WK, Kim YK, et al
    Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma.
    J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30071.
    PubMed     Abstract available

  132. KABASHIMA A, Hirsova P, Bronk SF, Hernandez MC, et al
    Fibroblast Growth Factor Receptor Inhibition induces loss of matrix MCL1 and necrosis in Cholangiocarcinoma.
    J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30073.
    PubMed     Abstract available

    January 2018
  133. WARDELL CP, Fujita M, Yamada T, Simbolo M, et al
    Genomic Characterization of Biliary Tract Cancers Identifies Driver Genes and Predisposing Mutations.
    J Hepatol. 2018 Jan 19. pii: S0168-8278(18)30021.
    PubMed     Abstract available

  134. ZHU HD, Guo JH, Huang M, Ji JS, et al
    Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: a multicentre trial.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30012.
    PubMed     Abstract available

    December 2017
  135. JIROUSKOVA M, Nepomucka K, Oyman-Eyrilmez G, Kalendova A, et al
    Plectin Controls Biliary Tree Architecture and Stability in Cholestasis.
    J Hepatol. 2017 Dec 19. pii: S0168-8278(17)32495.
    PubMed     Abstract available

    November 2017
  136. HARTL J, Ehlken H, Sebode M, Peiseler M, et al
    Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.
    J Hepatol. 2017 Nov 24. pii: S0168-8278(17)32445.
    PubMed     Abstract available

  137. LEI Z, Xia Y, Si A, Wang K, et al
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection.
    J Hepatol. 2017 Nov 16. pii: S0168-8278(17)32438.
    PubMed     Abstract available

    September 2017
  138. VERHOEVEN CJ, Selten JW, Roest HP, Farid WRR, et al
    Corrigendum to "MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation" [J Hepatol 2013; 59:1231-1238].
    J Hepatol. 2017 Sep 27. pii: S0168-8278(17)32279.

  139. WU H, Zhang H, Hu LY, Zhang TY, et al
    Is osteopontin a promising prognostic biomarker for cholangiocarcinoma?
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32269.

  140. LOOSEN SH, Roderburg C, Luedde T
    Reply to: "Is osteopontin a promising prognostic biomarker for cholangiocarcinoma?"
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32267.

    August 2017
    Sequencing of transporter genes in cholestasis: we are still learning.
    J Hepatol. 2017 Aug 21. pii: S0168-8278(17)32213.

  142. KARLSEN TH, Folseraas T, Thorburn D, Vesterhus M, et al
    Primary sclerosing cholangitis - a comprehensive review.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32196.
    PubMed     Abstract available

    July 2017
  143. DROGE C, Bonus M, Baumann U, Klindt C, et al
    Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32147.
    PubMed     Abstract available

  144. ZHANG S, Song X, Cao D, Xu Z, et al
    Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma induced in mice by AKT and Yap co-expression.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32149.
    PubMed     Abstract available

  145. FICKERT P, Wagner M
    Biliary bile acids in hepatobiliary injury - What is the link?
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)32008.
    PubMed     Abstract available

  146. SCHERBER PR, Lammert F, Glanemann M
    Gallstone disease: Optimal timing of treatment.
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)30214.

  147. TRIVEDI PJ, Scalera I, Slaney E, Laing RW, et al
    Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32135.
    PubMed     Abstract available

    Norursodeoxycholic acid in patients with primary sclerosing cholangitis: a new "urso saga" in the horizon?
    J Hepatol. 2017 Jul 1. pii: S0168-8278(17)32132.

    June 2017
  149. LOOSEN SH, Roderburg C, Kauertz KL, Pombeiro I, et al
    Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma.
    J Hepatol. 2017 Jun 28. pii: S0168-8278(17)32121.
    PubMed     Abstract available

    May 2017
  150. FICKERT P, Hirschfield GM, Denk G, Marschall HU, et al
    norUrsodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis.
    J Hepatol. 2017 May 18. pii: S0168-8278(17)32045.
    PubMed     Abstract available

    April 2017
    Reply to: Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis.
    J Hepatol. 2017 Apr 28. pii: S0168-8278(17)30253.

  152. CHEUNG AC, Juran BD, Moore RM, LaRusso NF, et al
    Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis.
    J Hepatol. 2017 Apr 28. pii: S0168-8278(17)30254.

  153. HIRSCHFIELD GM, Beuers U, Corpechot C, Invernizzi P, et al
    EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
    J Hepatol. 2017 Apr 17. pii: S0168-8278(17)30186.
    PubMed     Abstract available

  154. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline.
    J Hepatol. 2017 Apr 13. pii: S0168-8278(17)30108.
    PubMed     Abstract available

  155. SEIDEL RA, Claudel T, Schleser FA, Ojha NK, et al
    Impact of higher-order heme degradation products on hepatic function and hemodynamics.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30208.
    PubMed     Abstract available

  156. RIZVI S, Gores GJ
    Emerging Molecular Therapeutic Targets for Cholangiocarcinoma.
    J Hepatol. 2017 Apr 4. pii: S0168-8278(17)30197.
    PubMed     Abstract available

    March 2017
  157. JULICH-HAERTEL H, Urban SK, Krawczyk M, Willms A, et al
    Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30123.
    PubMed     Abstract available

  158. TACKE F
    Targeting hepatic macrophages to treat liver diseases.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30125.
    PubMed     Abstract available

    February 2017
  159. ORNTOFT NW, Munk OL, Frisch K, Ott P, et al
    Hepatobiliary transport kinetics of the conjugated bile acid tracer 11C-CSar quantified in healthy humans and patients by Positrion Emission Tomography (PET).
    J Hepatol. 2017 Feb 26. pii: S0168-8278(17)30120.
    PubMed     Abstract available

  160. KRONES E, Eller K, Pollheimer MJ, Racedo S, et al
    NorUrsodeoxycholic Acid Ameliorates Cholemic Nephropathy in Bile Duct Ligated Mice.
    J Hepatol. 2017 Feb 24. pii: S0168-8278(17)30116.
    PubMed     Abstract available

  161. MERINO-AZPITARTE M, Lozano E, Perugorria MJ, Esparza-Baquer A, et al
    SOX17 Regulates Cholangiocyte Differentiation and Acts as a Tumor Suppressor in Cholangiocarcinoma.
    J Hepatol. 2017 Feb 22. pii: S0168-8278(17)30114.
    PubMed     Abstract available

  162. NAKAGAWA R, Muroyama R, Saeki C, Goto K, et al
    miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30066.
    PubMed     Abstract available

  163. GUPTA K, Li Q, Fan JJ, Fong EL, et al
    Actomyosin Contractility Drives Bile Regurgitation as an Early Response During Obstructive Cholestasis.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30061.
    PubMed     Abstract available

  164. VESTERHUS M, Holm A, Hov JR, Nygard S, et al
    Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30052.
    PubMed     Abstract available

    January 2017
  165. MOEINI A, Sia D, Zhang Z, Camprecios G, et al
    Mixed hepatocellular-cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity.
    J Hepatol. 2017 Jan 23. pii: S0168-8278(17)30014.
    PubMed     Abstract available

  166. HANLEY J, Kumar Dhar D, Mazzacuva F, Fiadeiro R, et al
    Vps33b is Crucial for Structural and Functional Hepatocyte Polarity.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30005.
    PubMed     Abstract available

  167. EKSTEEN B, Heatherington J, Oshiomogo J, Panaccione R, et al
    Retraction notice to: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199].
    J Hepatol. 2017;66:254.

    December 2016
  168. SCHWINGE D, von Haxthausen F, Quaas A, Carambia A, et al
    Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related with IL-12 signaling.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30705.
    PubMed     Abstract available

    November 2016
  169. MONTE MJ, Alonso-Pena M, Briz O, Herraez E, et al
    ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia.
    J Hepatol. 2016 Nov 21. pii: S0168-8278(16)30652.
    PubMed     Abstract available

  170. LOFFLER MW, Chandran PA, Laske K, Schroeder C, et al
    Erratum to "Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient".
    J Hepatol. 2016 Nov 15. pii: S0168-8278(16)30613.

    October 2016
  171. RICKE J, Seidensticker M
    Molecular imaging and liver function assessment by hepatobiliary MRI.
    J Hepatol. 2016 Oct 8. pii: S0168-8278(16)30566.

  172. SCHRUMPF E, Kummen M, Valestrand L, Greiner TU, et al
    The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation.
    J Hepatol. 2016 Oct 5. pii: S0168-8278(16)30559.
    PubMed     Abstract available

  173. FICKERT P
    Bad memories from the gut may cause nightmares for the bile ducts - "Nothing fixes a thing so intensely in the memory as the wish to forget it.": Editorial for: "Gut and liver T cells of common clonal origin are detected in primary sclerosing cholangi
    J Hepatol. 2016 Oct 1. pii: S0168-8278(16)30543.

    September 2016
  174. VAQUERO J, Guedj N, Claperon A, Ho-Bouldoires TH, et al
    Epithelial-mesenchymal transition in cholangiocarcinoma: from clinical evidence to regulatory networks.
    J Hepatol. 2016 Sep 26. pii: S0168-8278(16)30537.
    PubMed     Abstract available

  175. HENRIKSEN EK, Jorgensen KK, Kaveh F, Holm K, et al
    Gut and liver T cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease.
    J Hepatol. 2016 Sep 16. pii: S0168-8278(16)30503.
    PubMed     Abstract available

    April 2016
  176. WESTBROOK RH, Dusheiko G, Williamson C
    Pregnancy and liver disease.
    J Hepatol. 2016;64:933-45.
    PubMed     Abstract available

    January 2016
  177. EKSTEEN B, Heatherington J, Oshiomogo J, Panaccione R, et al
    RETRACTED: Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (Psc) in Individuals with Inflammatory Bowel Disease.
    J Hepatol. 2016;64.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.